Navigation Links
Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)
Date:7/24/2014

are also leading the effort to advance this formulation for the clinical indication of psoriasis in Taiwan." Dr. KoChung Lin, CEO of PharmaEssentia said, "We are delighted to see the successful collaboration in the allowance for the KX2-391 IND for Actinic Keratosis by US FDA. We are also looking forward to applying for a Taiwan IND for KX2-391 ointment and launching our clinical development program for psoriasis in Taiwan.  Our collaboration with Kinex has been rewarding and we will use our joint momentum to bring KX2-391 Ointment into the clinic in Asia, expeditiously."

KX2-391 is also being developed as an oral agent for oncology indications and has been tested in four clinical studies, thus far.  In defining its pharmacological activity in tumor cells, both in vitro and in vivo,  KX2-391 has been shown to have potent activity against a wide range of solid tumors as well as leukemia cell lines, including cell lines that are resistant to commonly used cancer drugs. Kinex has also partnered with Hanmi Pharmaceuticals (Seoul, Korea) to develop the oral formulation of KX2-391 for oncology indications in the Korea and greater China Territory. In partnership with Hanmi Pharmaceuticals, the safety, tolerability and pharmacokinetics of KX2-391 have been studied in more than 120 patients in both solid and liquid tumors. A study of KX2-391 in combination with paclitaxel is currently being conducted in South Korea and sponsored through the collaboration with Hanmi Pharmaceuticals. 

Dr. Wing Kai Chan, Head of Clinical Operations for Asia Pacific for Kinex, said, "The ability to develop the new topical formulation of KX2-391 for hyper-proliferative skin diseases shows how Kinex is effectively building up its pipeline of drug candidates.  I look f
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
2. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
3. Hanmi Pharmaceuticals to Assign the Rights to Five New Territories to Kinex as Part of the Orascovery Program Strategic Plan
4. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
5. Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
6. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
7. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
8. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
9. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
10. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
11. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Calif., Nov. 10, 2011 Highlights from ... of action observed in placebo-controlled trials Comparative ... Safety and efficacy in post-prostatectomy population ... that multiple abstracts will be presented at the Sexual Medicine ...
... ALBANY, New York, November 10, 2011 According ... http://www.transparencymarketresearch.com ) " North America & Europe Minimally ...  " the prostate cancer minimally invasive surgical device ... be $14.2 billion in 2011 and expected to reach $24.9 ...
Cached Medicine Technology:Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 2Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 3Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 4Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 5Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016 2Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016 3Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016 4Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016 5
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 AlignLife of ... unable to afford certain items. During the holiday season, AlignLife ... collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of ... staff such joy, knowing that we are able to give ... had it not been for the generosity of our patients." ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and ... with 30 years of practice experience in Dallas, Texas, ... benefits of dietary detoxification. The second study is scheduled ... results from test patients who just completed a 21-day ... interest in conducting the study, Dr. Casad said, "About ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6
... Journal of the American College of Nutrition ... type 2 diabetes and metabolic syndrome of nut ... Tree nut (almonds, Brazil nuts, cashews, hazelnuts, macadamias, ... was associated with higher levels of high-density lipoprotein-cholesterol ...
... are not the best option for some young patients ... clinical remission after the initial weeks of intense chemotherapy ... of such pediatric ALL patients identified a subset of ... percent after additional chemotherapy rather than bone marrow transplantation. ...
... Denise Mann HealthDay Reporter , WEDNESDAY, April ... can help treat depression in people with Parkinson,s disease ... rigidity, researchers have found. Nearly 1 million people ... a progressive movement disorder marked by tremor, slowness and/or ...
... -- The spouses of cancer patients are at increased risk ... Researchers said the explanation might be that stress takes a ... Swedish cancer registry and the Swedish inpatient registry, researchers found ... to 29 percent in people whose partner had cancer. ...
... CHICAGO --- Pregnant women who are overweight with moderately elevated blood ... concern was for women who were obese or who had gestational ... health risks to the mom and baby. ... average for weight and blood sugar are at a higher risk ...
... April 11 (HealthDay News) -- A new nonsurgical method ... head injury patients, according to a new study. ... to increased pressure inside the skull, which can crush ... Monitoring brain pressure can help doctors determine the ...
Cached Medicine News:Health News:Tree nut consumption associated with lower body weight and lower prevalence of health risks 2Health News:Chemotherapy proves life-saving for some leukemia patients who fail induction therapy 2Health News:Chemotherapy proves life-saving for some leukemia patients who fail induction therapy 3Health News:Newer Antidepressants May Be Safe for Parkinson's Patients 2Health News:Newer Antidepressants May Be Safe for Parkinson's Patients 3Health News:New pregnancy risk for babies and moms 2Health News:Nonsurgical Method to Measure Brain Pressure Shows Promise 2
Pilling-Weck, medium-large clip size, 10mm, rotatable take apart...
Insert only, Pilling-Weck small clip size...
Pilling-Weck, small clip size, 10mm, rotatable take apart...
Insert only, Ethicon, small clip size...
Medicine Products: